Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BHARATHY SUNDARAM

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1396743720
CMS profile
630709
Location
SHERMAN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,430.30

102 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,430.30 102

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BHARATHY SUNDARAM

NPI 1396743720 · CMS profile ID 630709

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

SHERMAN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396743720?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BHARATHY SUNDARAM, NPI 1396743720, CMS profile ID 630709. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396743720?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). BHARATHY SUNDARAM, NPI 1396743720, CMS profile ID 630709. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396743720?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
BHARATHY SUNDARAM, NPI 1396743720, CMS profile ID 630709, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1396743720?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

102 matching records · $1,430.30 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 102 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 102.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $13.6406/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131795057 CMS
Amneal Pharmaceuticals LLC $16.8205/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139203180 CMS
ABBVIE INC. $7.5805/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106183371 CMS
SK Life Science, Inc. $24.3305/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154142237 CMS
ABBVIE INC. $5.5505/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106183367 CMS
ABBVIE INC. $2.0005/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106183369 CMS
UCB, Inc. $21.5205/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143471366 CMS
ABBVIE INC. $7.8305/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106183365 CMS
ABBVIE INC. $4.5105/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106183363 CMS
ABBVIE INC. $7.7305/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106183361 CMS
PFIZER INC. $9.2105/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131918303 CMS
PFIZER INC. $12.7904/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131922433 CMS
Lundbeck LLC $21.3004/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145973346 CMS
ABBVIE INC. $5.1204/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106183359 CMS
PFIZER INC. $25.2004/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131825544 CMS
ABBVIE INC. $5.5904/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106183357 CMS
MDD US Operations, LLC $14.4904/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147768173 CMS
ABBVIE INC. $10.9604/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106183355 CMS
EMD Serono, Inc. $23.6904/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120238234 CMS
Ipsen Biopharmaceuticals, Inc $26.9003/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091951331 CMS
ABBVIE INC. $6.7203/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106183353 CMS
Kyowa Kirin, Inc. $29.3103/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127026281 CMS
SK Life Science, Inc. $30.6403/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154142211 CMS
Sumitomo Pharma America, Inc. $21.9903/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148925283 CMS
ABBVIE INC. $6.9103/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106183351 CMS
Genentech USA, Inc. $18.3003/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132981546 CMS
ABBVIE INC. $8.3803/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106183349 CMS
Lilly USA, LLC $13.7503/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136067840 CMS
PFIZER INC. $18.7403/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131825338 CMS
LivaNova USA, Inc. $19.4503/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152795637 CMS
LivaNova USA, Inc. $20.5003/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152795639 CMS
ABBVIE INC. $5.6202/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106183347 CMS
ABBVIE INC. $9.8502/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106183345 CMS
Genentech USA, Inc. $19.8602/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132981548 CMS
Novartis Pharmaceuticals Corporation $13.6802/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087156685 CMS
PFIZER INC. $5.8602/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132021877 CMS
Amneal Pharmaceuticals LLC $29.4302/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139203178 CMS
PFIZER INC. $6.1902/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131910054 CMS
ABBVIE INC. $31.4402/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106183343 CMS
Neurocrine Biosciences, Inc. $32.9202/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150821693 CMS
Lilly USA, LLC $14.9702/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136080972 CMS
ABBVIE INC. $4.2402/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106183339 CMS
ABBVIE INC. $3.0502/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106183341 CMS
PFIZER INC. $7.9101/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131911697 CMS
Sumitomo Pharma America, Inc. $28.5801/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148925281 CMS
ABBVIE INC. $3.5601/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106183337 CMS
ABBVIE INC. $7.7701/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106183335 CMS
Sumitomo Pharma America, Inc. $18.6501/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148925279 CMS
ABBVIE INC. $10.1801/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106183333 CMS
Amneal Pharmaceuticals LLC $15.6801/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139203176 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $23,570.33 41
PY2020 $4,179.05 11
PY2021 $11,338.02 52
PY2022 $11,638.47 96
PY2023 $4,542.79 114
PY2024 $1,430.30 102
PY2025 $4,047.59 103

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,130,213.78 43
PY2024 Principal investigator $1,911,271.75 55
PY2023 Principal investigator $1,650,111.56 34
PY2022 Principal investigator $1,216,451.66 20
PY2021 Recipient $703.81 1
PY2021 Principal investigator $500,933.85 17
PY2020 Recipient $1,500.00 1
PY2020 Principal investigator $491,302.31 7
PY2019 Recipient $2,000.00 2
PY2019 Principal investigator $265,154.41 83

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

43 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $4,550.00 12/19/2025 Non-covered Recipient Entity
TEXOMA NEUROLOGY ASSOC P A TEXAS INSTITUTE FOR NEUROLOGICAL DISORDERS
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211663735
Principal investigator 1 Novartis Pharmaceuticals Corporation $244,616.24 12/01/2025 Non-covered Recipient Entity
TEXAS INSTITUTE FOR NEUROLOGICAL DISORDERS
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190307677
Principal investigator 1 Boston Scientific Corporation $765.00 11/25/2025 Non-covered Recipient Entity
TEXOMA NEUROLOGY ASSOCIATES PA
US DBS REGISTRY No dispute reported 06/30/2026 1207576665
Principal investigator 1 Genentech, Inc. $10,680.00 11/06/2025 Non-covered Recipient Entity
TEXOMA NEUROLOGY ASSOC P A TEXAS INSTITUTE FOR NEUROLOGICAL DISORDERS
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211663730
Principal investigator 1 Genentech, Inc. $5,810.00 10/28/2025 Non-covered Recipient Entity
TEXOMA NEUROLOGY ASSOC P A TEXAS INSTITUTE FOR NEUROLOGICAL DISORDERS
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211663706
Principal investigator 1 Genentech, Inc. $2,389.00 10/15/2025 Non-covered Recipient Entity
TEXOMA NEUROLOGY ASSOC P A TEXAS INSTITUTE FOR NEUROLOGICAL DISORDERS
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211663727
Principal investigator 1 Novartis Pharmaceuticals Corporation $33,422.18 10/08/2025 Non-covered Recipient Entity
TEXAS INSTITUTE FOR NEUROLOGICAL DISORDERS
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190307673
Principal investigator 1 Genentech, Inc. $1,464.00 09/19/2025 Non-covered Recipient Entity
TEXOMA NEUROLOGY ASSOC P A TEXAS INSTITUTE FOR NEUROLOGICAL DISORDERS
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211663723
Principal investigator 1 Genentech, Inc. $2,389.00 09/17/2025 Non-covered Recipient Entity
TEXOMA NEUROLOGY ASSOC P A TEXAS INSTITUTE FOR NEUROLOGICAL DISORDERS
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211663719
Principal investigator 1 Ipsen Pharma SAS $1,888.50 08/08/2025 Non-covered Recipient Entity
Texas Institute For Neurological Disorders
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305753
Principal investigator 1 Ipsen Pharma SAS $1,746.00 08/08/2025 Non-covered Recipient Entity
Texas Institute For Neurological Disorders
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305755
Principal investigator 1 Ipsen Pharma SAS $1,746.00 08/08/2025 Non-covered Recipient Entity
Texas Institute For Neurological Disorders
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305757
Principal investigator 1 Ipsen Pharma SAS $1,746.00 08/08/2025 Non-covered Recipient Entity
Texas Institute For Neurological Disorders
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305759
Principal investigator 1 Ipsen Pharma SAS $1,746.00 08/08/2025 Non-covered Recipient Entity
Texas Institute For Neurological Disorders
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305761
Principal investigator 1 Ipsen Pharma SAS $1,746.00 08/08/2025 Non-covered Recipient Entity
Texas Institute For Neurological Disorders
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305763
Principal investigator 1 Ipsen Pharma SAS $1,746.00 08/08/2025 Non-covered Recipient Entity
Texas Institute For Neurological Disorders
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305765
Principal investigator 1 Ipsen Pharma SAS $1,746.00 08/08/2025 Non-covered Recipient Entity
Texas Institute For Neurological Disorders
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305767
Principal investigator 1 Ipsen Pharma SAS $1,746.00 08/08/2025 Non-covered Recipient Entity
Texas Institute For Neurological Disorders
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305769
Principal investigator 1 Genentech, Inc. $2,106.00 07/21/2025 Non-covered Recipient Entity
TEXOMA NEUROLOGY ASSOC P A TEXAS INSTITUTE FOR NEUROLOGICAL DISORDERS
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211663717
Principal investigator 1 Boston Scientific Corporation $605.75 05/27/2025 Non-covered Recipient Entity
TEXOMA NEUROLOGY ASSOCIATES PA
US DBS REGISTRY No dispute reported 06/30/2026 1207576663
Principal investigator 1 Genentech, Inc. $4,495.00 05/21/2025 Non-covered Recipient Entity
TEXOMA NEUROLOGY ASSOC P A TEXAS INSTITUTE FOR NEUROLOGICAL DISORDERS
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211663710
Principal investigator 1 Genentech, Inc. $2,090.00 05/09/2025 Non-covered Recipient Entity
TEXOMA NEUROLOGY ASSOC P A TEXAS INSTITUTE FOR NEUROLOGICAL DISORDERS
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211663702
Principal investigator 1 Ipsen Pharma SAS $1,062.00 04/04/2025 Non-covered Recipient Entity
Texas Institute For Neurological Disorders
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305747
Principal investigator 1 Ipsen Pharma SAS $1,062.00 04/04/2025 Non-covered Recipient Entity
Texas Institute For Neurological Disorders
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305749
Principal investigator 1 Ipsen Pharma SAS $1,156.50 04/04/2025 Non-covered Recipient Entity
Texas Institute For Neurological Disorders
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305751
Principal investigator 1 Genentech, Inc. $4,495.00 04/02/2025 Non-covered Recipient Entity
TEXOMA NEUROLOGY ASSOC P A TEXAS INSTITUTE FOR NEUROLOGICAL DISORDERS
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211663714
Principal investigator 1 Eli Lilly and Company $365.70 04/01/2025 Non-covered Recipient Entity
TEXOMA NEUROLOGY ASSOCIATES PA
PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) No dispute reported 06/30/2026 1187891768
Principal investigator 1 GENZYME CORPORATION $3,474.36 03/17/2025 Non-covered Recipient Entity
Multiple Doctors
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226119887
Principal investigator 1 Novartis Pharmaceuticals Corporation $38,055.40 02/20/2025 Non-covered Recipient Entity
TEXAS INSTITUTE FOR NEUROLOGICAL DISORDERS
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190304283
Principal investigator 1 Ipsen Pharma SAS $1,062.00 02/17/2025 Non-covered Recipient Entity
Texas Institute For Neurological Disorders
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305729
Principal investigator 1 Ipsen Pharma SAS $1,062.00 02/17/2025 Non-covered Recipient Entity
Texas Institute For Neurological Disorders
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305731
Principal investigator 1 Ipsen Pharma SAS $1,809.00 02/17/2025 Non-covered Recipient Entity
Texas Institute For Neurological Disorders
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305733
Principal investigator 1 Ipsen Pharma SAS $2,203.50 02/17/2025 Non-covered Recipient Entity
Texas Institute For Neurological Disorders
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305735
Principal investigator 1 Ipsen Pharma SAS $1,156.50 02/17/2025 Non-covered Recipient Entity
Texas Institute For Neurological Disorders
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305737
Principal investigator 1 Ipsen Pharma SAS $1,062.00 02/17/2025 Non-covered Recipient Entity
Texas Institute For Neurological Disorders
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305739
Principal investigator 1 Ipsen Pharma SAS $2,203.50 02/17/2025 Non-covered Recipient Entity
Texas Institute For Neurological Disorders
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305741
Principal investigator 1 Ipsen Pharma SAS $1,156.50 02/17/2025 Non-covered Recipient Entity
Texas Institute For Neurological Disorders
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305743
Principal investigator 1 Ipsen Pharma SAS $2,521.50 02/17/2025 Non-covered Recipient Entity
Texas Institute For Neurological Disorders
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305745
Principal investigator 1 Genentech, Inc. $5,810.00 02/14/2025 Non-covered Recipient Entity
TEXOMA NEUROLOGY ASSOC P A TEXAS INSTITUTE FOR NEUROLOGICAL DISORDERS
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211663699
Principal investigator 1 GENZYME CORPORATION $14,049.44 02/10/2025 Non-covered Recipient Entity
Multiple Doctors
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226119883
Principal investigator 1 Novartis Pharmaceuticals Corporation $46,184.00 01/28/2025 Non-covered Recipient Entity
TEXAS INSTITUTE FOR NEUROLOGICAL DISORDERS
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190304285
Principal investigator 1 Novartis Pharmaceuticals Corporation $284,303.69 01/02/2025 Non-covered Recipient Entity
TEXAS INSTITUTE FOR NEUROLOGICAL DISORDERS
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190307675
Principal investigator 1 Novartis Pharmaceuticals Corporation $384,720.52 01/01/2025 Non-covered Recipient Entity
TEXAS INSTITUTE FOR NEUROLOGICAL DISORDERS
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190307679